Gynecological malignancies are the second most common cancer in women worldwide. With the continuous deepening of research, the rise of targeted therapy and immunotherapy, cancer therapy has entered a new era and obtained certain clinical effect. However, the overall survival (OS) of Gynecological cancer patients did not significantly improve, as the emergence of therapeutic resistance. Tumor microenvironment (TME) is a complex and comprehensive system. Inhibitive changes and heterogeneous characteristics of TME have great influence on the occurrence, development, therapeutic difference, and drug resistance of gynecological malignancies. At present, the challenge of therapy is the lack of accurate screening of the dominant population and systematic research on the mechanism of drug resistance. An in-depth understand of the role of TME and the mechanism of drug resistance, can provide new opportunities for developing advanced gynecological malignancies treatments and enhancing drug efficacy.
This Research Topic aims at unraveling the mechanisms of TME and drug resistance in gynecologic malignancies. Our goal is to promote the development of precision therapy and combination therapy, avoid and overcome the occurrence of drug resistance to achieve more efficient and longer-lasting therapeutic effects.
We welcome submissions of Original Research, Reviews, and Mini-Reviews, covering but not limited to the below subtopics:
• Mechanisms of which and how cells and molecules in the tumor microenvironment to suppress immune response and allow cancer to evade attacking.
• Effect of TME on therapeutic resistance.
• According to the heterogeneity of TME, studies on targeted tumor microenvironment which can achieve individualized comprehensive treatment.
• Engineering nanoparticles delivery system, enhanced the ability of drug targeting tumor, reduced toxicity and improved anti-tumor activity.
• Explored the new direction of multimodal therapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gynecological malignancies are the second most common cancer in women worldwide. With the continuous deepening of research, the rise of targeted therapy and immunotherapy, cancer therapy has entered a new era and obtained certain clinical effect. However, the overall survival (OS) of Gynecological cancer patients did not significantly improve, as the emergence of therapeutic resistance. Tumor microenvironment (TME) is a complex and comprehensive system. Inhibitive changes and heterogeneous characteristics of TME have great influence on the occurrence, development, therapeutic difference, and drug resistance of gynecological malignancies. At present, the challenge of therapy is the lack of accurate screening of the dominant population and systematic research on the mechanism of drug resistance. An in-depth understand of the role of TME and the mechanism of drug resistance, can provide new opportunities for developing advanced gynecological malignancies treatments and enhancing drug efficacy.
This Research Topic aims at unraveling the mechanisms of TME and drug resistance in gynecologic malignancies. Our goal is to promote the development of precision therapy and combination therapy, avoid and overcome the occurrence of drug resistance to achieve more efficient and longer-lasting therapeutic effects.
We welcome submissions of Original Research, Reviews, and Mini-Reviews, covering but not limited to the below subtopics:
• Mechanisms of which and how cells and molecules in the tumor microenvironment to suppress immune response and allow cancer to evade attacking.
• Effect of TME on therapeutic resistance.
• According to the heterogeneity of TME, studies on targeted tumor microenvironment which can achieve individualized comprehensive treatment.
• Engineering nanoparticles delivery system, enhanced the ability of drug targeting tumor, reduced toxicity and improved anti-tumor activity.
• Explored the new direction of multimodal therapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
